The cancer research company raised $130m from its initial public offering.
US-based biopharmaceutical company Clovis Oncology priced the shares for its initial public offering (IPO) on 15th November, offering 10 million shares at $13.00 per share, raising a total of $130m. The underwriters were given a 30 day option to purchase an additional 1.5 million shares.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
